Shares of Haemonetics Corporation (NYSE:HAE – Get Free Report) have received an average rating of “Moderate Buy” from the eleven research firms that are covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $79.8889.
Several equities research analysts recently issued reports on the company. Mizuho cut their price target on Haemonetics from $80.00 to $70.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. BTIG Research reiterated a “buy” rating and issued a $88.00 price target on shares of Haemonetics in a research note on Friday, February 6th. Wall Street Zen cut Haemonetics from a “buy” rating to a “hold” rating in a research note on Saturday. Barrington Research set a $94.00 price target on Haemonetics in a research note on Friday, February 6th. Finally, Citigroup reduced their target price on Haemonetics from $75.00 to $70.00 and set a “neutral” rating on the stock in a report on Wednesday, March 11th.
Read Our Latest Analysis on HAE
Haemonetics Stock Performance
Haemonetics (NYSE:HAE – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The firm had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. During the same period in the prior year, the firm posted $1.24 EPS. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, equities analysts forecast that Haemonetics will post 5.28 EPS for the current year.
Institutional Trading of Haemonetics
Large investors have recently modified their holdings of the stock. Federated Hermes Inc. grew its holdings in shares of Haemonetics by 1,405.7% during the 3rd quarter. Federated Hermes Inc. now owns 46,104 shares of the medical instruments supplier’s stock worth $2,247,000 after purchasing an additional 43,042 shares in the last quarter. Isthmus Partners LLC grew its holdings in shares of Haemonetics by 36.5% during the 3rd quarter. Isthmus Partners LLC now owns 61,702 shares of the medical instruments supplier’s stock worth $3,007,000 after purchasing an additional 16,505 shares in the last quarter. Invenomic Capital Management LP grew its holdings in shares of Haemonetics by 1,691.5% during the 3rd quarter. Invenomic Capital Management LP now owns 498,317 shares of the medical instruments supplier’s stock worth $24,288,000 after purchasing an additional 470,502 shares in the last quarter. Skylands Capital LLC grew its holdings in shares of Haemonetics by 195.4% during the 3rd quarter. Skylands Capital LLC now owns 81,369 shares of the medical instruments supplier’s stock worth $3,966,000 after purchasing an additional 53,819 shares in the last quarter. Finally, Barrow Hanley Mewhinney & Strauss LLC grew its holdings in shares of Haemonetics by 16.5% during the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 559,972 shares of the medical instruments supplier’s stock worth $27,293,000 after purchasing an additional 79,138 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.
Haemonetics Company Profile
Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.
The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.
Featured Articles
- Five stocks we like better than Haemonetics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.
